Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
ID: 349801Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349801

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems." This initiative aims to foster collaborations between academic institutions and industrial partners to advance imaging technologies that address critical challenges in cancer detection, diagnosis, and treatment. The program is particularly focused on innovative solutions that enhance imaging capabilities tailored to the needs of end-users, thereby contributing to improved cancer research outcomes. Grants are available for projects lasting up to five years, with a maximum budget of $500,000 in direct costs per year, and applications are due by January 7, 2027. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-259-Full-Announcement.html
    PAR-23-259.html
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), has issued a Notice of Funding Opportunity (NOFO) titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems." This funding aims to foster collaborations between academic institutions and industrial entities to translate scientific advancements in imaging technologies to tackle cancer-related challenges. Notably, applications must feature strategic alliances that can identify and implement technological solutions for detection, diagnosis, and treatment of cancer. Eligible applicants include a broad array of organizations, such as higher education institutions, nonprofits, for-profits, and local, state, and tribal governments. Grants will cover projects up to five years, with budgets capped at $500,000 direct costs per year. Applications may involve optional clinical trials, but basic research or commercial production is not supported. Key dates include an open application period starting September 5, 2023, leading to multiple review cycles. The NOFO emphasizes the importance of innovation in imaging capabilities tailored to end-user needs, setting the stage for advancements in clinical and non-clinical cancer research. The successful applicants will contribute to the development of enhanced imaging tools that improve cancer detection and treatment outcomes, addressing unmet needs in the current healthcare environment.
    Similar Opportunities
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic and industrial entities to enhance imaging technologies for cancer-related challenges. This initiative encourages innovative proposals that detail mechanisms for clinical relevance and operational feasibility, with a focus on advancing the development and validation of imaging systems that can improve cancer detection, diagnosis, and treatment. Funding is available for projects with budgets capped at $500,000 per year for up to five years, and applications must involve at least one academic and one industrial investigator. Interested applicants should submit their proposals electronically by January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for R01 grant applications focused on the integration of imaging and fluid-based tumor monitoring in cancer therapy. The objective is to enhance research designs that utilize imaging and liquid biopsy assays to assess treatment responses and the emergence of resistance in cancer patients, thereby advancing precision medicine in cancer treatment. This initiative is critical for improving diagnostic techniques and patient monitoring strategies across various cancer types. Eligible applicants, including universities, for-profit organizations, and nonprofits, can apply for grants with a maximum budget of $500,000 per year for projects lasting up to five years. Applications will be accepted from January 5, 2025, until January 8, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer inflammation through innovative molecular imaging techniques. This initiative encourages applications that leverage in vivo imaging methods to provide deeper insights into the dynamic interactions between inflammation and cancer, moving beyond traditional in vitro approaches. The program seeks multidisciplinary collaborations among cancer biologists and imaging scientists to develop integrated imaging strategies and molecular probes for real-time monitoring of inflammatory responses within the tumor microenvironment. Interested applicants can apply for up to $500,000 annually for a maximum of five years, with the application deadline set for January 8, 2028. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html.
    Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)." This initiative aims to support innovative research projects that integrate advanced imaging techniques, biomarkers, and digital pathomics to enhance the early detection of aggressive cancers and precancerous lesions, thereby improving diagnostic accuracy and reducing overdiagnosis. The program emphasizes the importance of multidisciplinary collaboration in cancer research, particularly focusing on high-risk cancers such as pancreatic and lung cancers. Interested applicants, including higher education institutions, nonprofits, and government entities, must submit their proposals by September 7, 2025, and can find additional information and application details at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance cancer research methodologies, particularly in areas such as diagnostics, treatment, and addressing health disparities. The funding program is part of the National Cancer Institute's (NCI) Innovative Molecular Analysis Technologies (IMAT) Program, with a total estimated funding of $4.3 million available for approximately 10 awards, each capped at $300,000 per year for projects lasting up to three years. Interested applicants must submit their proposals by October 3, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
    In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems" under the cooperative agreement mechanism (UG3/UH3), aimed at advancing optical imaging technologies to address the challenges of light scattering in biological tissues. This initiative seeks to develop next-generation non-invasive or minimally-invasive optical imaging techniques that enhance penetration depth and resolution, thereby improving diagnostic and research capabilities in biomedical fields. With a total funding commitment of approximately $4.9 million available over a maximum project period of three years, eligible applicants include higher education institutions, non-profits, and small businesses, all of which must submit their proposals electronically through Grants.gov by February 7, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" (R01 - Clinical Trial Optional), aimed at fostering collaborations between academic and industrial organizations to develop innovative healthcare solutions. This initiative seeks to stimulate the translation of scientific discoveries into practical tools and methods for diagnosing and treating diseases, with a focus on interdisciplinary teamwork and addressing significant health challenges, particularly in low-resource settings. Eligible applicants can request funding up to $499,000 annually for a maximum project duration of five years, with the application deadline set for January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.